CVS Health Corporation
Customer Exposure
CVS is McKesson's largest customer at ~24% of revenues and ~21% of trade receivables; partnership runs to June 2027, concentrated in the North American Pharmaceutical segment.
Relevance 95·Dependency 90·Confidence 98
Source evidence
“Sales to our largest customer, CVS Health Corporation ("CVS"), accounted for approximately 24% of our total consolidated revenues in fiscal 2026.”
United States
Revenue Exposure
Core pharmaceutical distribution, RxTS, and Medical-Surgical businesses operate in the U.S.; ~38,000 of 43,000+ employees are U.S.-based.
Relevance 95·Dependency 90·Confidence 97
Source evidence
“We had approximately 38,000 employees in the U.S., 5,000 employees in Canada, and 400 employees in the rest of the world.”
CVS Health Corporation
Customer Exposure
CVS Health is McKesson's largest customer at ~24% of consolidated revenues and ~21% of trade receivables; loss or payment default would be materially adverse.
Relevance 95·Dependency 90·Confidence 98
Source evidence
“A material default in payment, a material reduction in purchases from GPOs or any other large customers, or the loss of a large customer or GPO could have a material adverse impact on our financial position, results of operations, and liquidity.”
pharmaceutical and other products from manufacturers
Supplier Dependency
Top-10 suppliers are ~71% of purchases; supplier loss and manufacturer pricing/consolidation materially affect supply and gross margin.
Relevance 90·Dependency 88·Confidence 95
Source evidence
“The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable.”
Pharmaceutical products
Supplier Dependency
McKesson relies on third-party suppliers for pharmaceutical products; supplier failures from regulatory, raw material, manufacturing, or geopolitical causes can materially disrupt operations.
Relevance 90·Dependency 85·Confidence 96
Source evidence
“We rely on third parties for the supply of pharmaceutical and other products, and our operations are subject to our suppliers' continued ability to supply the products that we require.”
Biopharma companies
Customer Exposure
Prescription Technology Solutions provides logistics, dispensing support, and technology services to biopharma customers across the product lifecycle.
Relevance 85·Dependency 80·Confidence 90
Source evidence
“third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle”
Controlled Substances Act / DEA regulation
Regulatory Exposure
Pharmaceutical distribution requires DEA/state registrations, security standards, and costly controlled-substance monitoring programs.
Relevance 85·Dependency 75·Confidence 93
Source evidence
“We maintain extensive controlled substance monitoring and reporting programs at considerable expense in order to help us meet those standards.”
IRA / healthcare reform (OBBBA, 340B, drug pricing laws)
Regulatory Exposure
Healthcare reform (IRA, OBBBA, CMS rulemaking, 340B litigation, state drug pricing) could reduce reimbursement and distribution economics.
Relevance 85·Dependency 70·Confidence 92
Source evidence
“certain changes in reimbursement methodologies (including government rates) for pharmaceuticals, medical treatments, and related services reduce profit margins for us and our customers”
Cencora, Inc.
Competitive Exposure
Cencora is a named primary competitor in pharmaceutical distribution, wholesaling, and logistics.
Relevance 85·Dependency 60·Confidence 97
Source evidence
“Our primary competitors in distribution, wholesaling, and logistics are Cencora, Inc. and Cardinal Health, Inc.”
Cardinal Health, Inc.
Competitive Exposure
Cardinal Health is a named primary competitor in distribution and also competes in Oncology & Multispecialty via combined distribution/GPO/provider capabilities.
Relevance 85·Dependency 60·Confidence 97
Source evidence
“Certain competitors also offer combinations of distribution, GPO, and provider services capabilities, including Cencora, Inc. and Cardinal Health, Inc.”
Generic pharmaceuticals
Supplier Dependency
Generic distribution business exposed to product availability and pricing risks; ClarusONE sourcing failures or input cost increases could hurt margins; patent infringement claims may not be fully indemnified.
Relevance 80·Dependency 75·Confidence 95
Source evidence
“Our generic pharmaceuticals distribution business is subject to both product availability and pricing risks.”
Group purchasing organizations (GPOs)
Customer Exposure
GPOs function as purchasing agents for member hospitals and pharmacies; top-10 customers (incl. GPOs) represent ~73% of revenues, creating significant sales and credit concentration.
Relevance 80·Dependency 70·Confidence 95
Source evidence
“We also have agreements with GPOs, each of which functions as a purchasing agent on behalf of member hospitals, pharmacies and other healthcare providers, as well as with government entities and agencies.”
GPOs and government entities
Revenue Exposure
GPOs act as purchasing agents for hospitals, pharmacies, and providers; government contracts carry funding and compliance risks affecting demand.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“each of which functions as a purchasing agent on behalf of member hospitals, pharmacies, and other healthcare providers, as well as with government entities and agencies”
U.S. non-acute healthcare providers
Customer Exposure
Medical-Surgical Solutions distributes to U.S. providers in ambulatory and extended care settings.
Relevance 75·Dependency 70·Confidence 90
Source evidence
“provides medical-surgical, laboratory, and pharmaceutical distribution, logistics, and other services to U.S. healthcare providers operating in the non-acute settings”
Biopharma and life sciences partners
Customer Exposure
RxTS serves biopharma/life sciences partners with 650+ brand connections, generating medication access, affordability, and adherence service revenue.
Relevance 75·Dependency 60·Confidence 93
Source evidence
“has supported over 650 biopharma brands representing most therapeutic areas”
Inflation raises operating and inventory purchase costs and reduces consumer commercial spending; compounded by supply chain disruptions, labor tightness, tariffs, and interest rates.
Relevance 70·Dependency 60·Confidence 94
Source evidence
“Inflationary conditions result in increased costs associated with our normal business operations and decreased levels of consumer commercial spending”
Regulatory approvals for Apollo Medical-Surgical investment
Regulatory Exposure
The ~$1.25B Apollo Funds convertible preferred investment in Medical-Surgical Solutions is subject to regulatory approvals and customary closing conditions.
Relevance 70·Dependency 55·Confidence 95
Source evidence
“This transaction closing is subject to regulatory approvals and customary closing conditions.”
Florida Cancer Specialists & Research Institute (FCS)
Revenue Exposure
McKesson acquired 70% of Core Ventures, the business and administrative services organization established by FCS, expanding its oncology platform.
Relevance 70·Dependency 55·Confidence 90
Source evidence
“a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC, (“FCS”). We acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash”
ClarusONE (JV with Walmart Inc.)
Supplier Dependency
Generic drug sourcing for U.S. pharmaceutical distribution runs through the ClarusONE JV with Walmart, a key supply arrangement.
Relevance 62·Dependency 45·Confidence 95
Source evidence
“We also source generic pharmaceutical drugs through our ClarusONE Sourcing Services LLP joint venture with Walmart Inc.”
North American Pharmaceutical includes Canadian wholesale and retail distribution operations, one of the largest in Canada.
Relevance 60·Dependency 50·Confidence 95
Source evidence
“Our Canadian pharmaceutical business is one of the largest pharmaceutical wholesale and retail distributors in Canada.”
AI technologies
Technology Dependency
McKesson relies increasingly on AI in internal operations and business processes; third-party AI tools and data rights affect data services growth and AI objectives.
Relevance 60·Dependency 50·Confidence 90
Source evidence
“Reliance on third-party AI tools and solutions may expose us to risks that are outside of our control, including compliance gaps.”
Competition/antitrust law enforcement
Legal Exposure
FTC/DOJ enforcement and potential restrictions on vertical healthcare ownership could delay or block strategic transactions central to the growth strategy.
Relevance 55·Dependency 45·Confidence 88
Source evidence
“Some of our strategic transactions may require review by competition regulators, with potential delays or other unfavorable outcomes.”
OECD Pillar Two global minimum tax
Tax Exposure
Pillar Two introduces a 15% country-by-country global minimum tax; McKesson concluded no expected material impact, but ultimate effect may differ from estimates.
Relevance 55·Dependency 40·Confidence 93
Source evidence
“While we evaluated the implications of these measures and concluded that they are not expected to have a material impact on our consolidated financial position, results of operations, or cash flows, their ultimate impact may differ from our estimates.”
Artificial intelligence
Demand Driver
Company invests in data and analytics supporting growth priorities including AI to improve productivity and enhance products and services.
Relevance 55·Dependency 35·Confidence 90
Source evidence
“we invest in data and analytics to support our growth priorities, including artificial intelligence (“AI”)”